スニチニブで治療されたクリアセル腎臓がん患者における臓器毒性の発生率と罹患率と生存への影響:参照がんセンターの経験
Agata Sałek-Zań1, Mirosława Püsküllüoğlu1, Justyna Jaworska1
1Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.
Frontiers in oncology
|September 5, 2025
まとめ
スニチニブで治療された進行したクリア細胞腎臓がん (ccRCC) の患者では,投与量削減を必要とする心臓毒性や胃腸疾患などの特定の毒性は,全生存率の改善と関連しており,治療の有効性の潜在的な指標を示唆しています.
科学分野:
- 腫瘍学
- 薬理学について
- 臨床研究
背景:
- ティロシンキナーゼ阻害剤 (TKI) は,進行したクリア細胞腎臓がん (ccRCC) の標準薬です.
- TKIの毒性は最適な投与を阻害し,臨床結果に影響を与える可能性があります.
- 毒性のパターンを理解することは,CCRCC治療の管理に不可欠です.
研究 の 目的:
- ファーストラインのスニチニブを投与されたCCRCC患者における臓器毒性の発生率と罹患率を評価する.
- これらの毒性が全生存期 (OS) に与える影響を評価する.
- 投与量変更と生存結果との関係を調べる.
主な方法:
- ファーストラインのスニチニブで治療された96人のCCRCC患者の遡及分析.
- 臓器への毒性,用量遅延,用量減少に関するデータ
- 毒性,用量変更,およびOSの間の相関を決定するための統計分析.
主要な成果:
- 胃腸 (76. 0%),疲労 (61. 5%),心血管 (49. 0%) の毒性は最も一般的であり,81. 3%が多臓器毒性であった.
- 主に消化器系および心血管系の問題のために,患者の66. 7%で投与量減少が必要でした.
- 心臓毒性 (p=0. 017),心臓毒性 (p=0. 012),血液毒性 (p=0. 004) または胃腸毒性 (p=0. 004) に起因する用量減少がOSの改善と相関している.
結論:
- 特定の毒性 (心臓毒性,消化器系,血液学) は,CCRCCにおけるスニチニブ治療の有効性を示す可能性があります.
- これらの発見は,毒性の管理と治療継続のバランスを取ることの重要性を強調しています.
- 毒性プロファイルに基づいて,CCRCCにおけるTKI治療の最適化のための戦略をさらに洗練することができる.
さらに関連する動画
関連する概念動画
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
01:17Factors Affecting Renal Clearance: Renal Impairment
154
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
154
01:06Renal Drug Clearance: Overview
321
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
321
01:11Renal Failure: Dose Adjustments
151
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
151
01:29Acute Kidney Injury III: Clinical Manifestations
86
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
86
01:29Acute Kidney Injury II: Pathophysiology
70
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
70